Other Briefings
Beyond Oil: How Gulf Disruptions Are Rewiring Global Supply Chains
The 2026 West Asia conflict has triggered a systemic, multi-sector shock, with disruptions to urea and helium exports from the Gulf constraining global agriculture and semiconductor manufacturing supply chains.
India’s Race to Manufacture Affordable Obesity Drugs Amid Ozempic’s Market Entry
India’s obesity-drug market is transforming as semaglutide goes off patent, driving Ozempic’s generic manufacturing, price shifts, and new opportunities in GLP-1 therapies.
New Drug Manufacturing Rules 2026: India’s 3-Tier Change Classification & DCGI Licensing Overhaul
Navigate the 2026 drug manufacturing reforms: a guide to India’s mandatory pharma change reporting, 3-tier risk classifications, and standardized Drugs Controller General of India (DCGI) licensing norms.
India’s Semiconductor Sector: Tracking Government Support and Investment Trends
As of March 2026, India hosts around 7 percent of the world’s semiconductor GCCs and employs nearly 20 percent of the global chip design workforce.
Investing in Sriperumbudur: Tamil Nadu’s High-Value Manufacturing Corridor
Sriperumbudur in Tamil Nadu is one of India’s most strategic high-value corridors, propelled by electronics production and a strong global OEM presence, including Foxconn. The region offers a scalable and de-risked platform for investment in India through 2026.
What Counts as an “Industry” Under Indian Law? Supreme Court to Decide on March 17-18
India’s Supreme Court will revisit the definition of “industry” under the Industrial Disputes Act, 1947, a ruling that could directly influence the interpretation and implementation of the Industrial Relations Code, 2020.
India’s Orange Economy: Creative Industries Outlook After Budget 2026
As of 2026, India’s orange economy is emerging as a high-growth services opportunity, spanning media, live concerts, AVGC, and creative industries, supported by policy reform.
India Fast-Tracks New Drug & Clinical Trial Approvals with 2026 NDCT Amendments
India’s 2026 amendments to the New Drug and Clinical Trials (NDCT) Rules, 2019, materially improve the operating environment for pharmaceutical companies, contract manufacturers, and foreign investors by compressing approval timelines and reducing pre-licensing bottlenecks.
